<DOC>
	<DOC>NCT01392872</DOC>
	<brief_summary>Multiple Sclerosis is the first cause of neurological handicap in France. The importance of cognitive disabilities, their evaluation and their impact on patients' life have only been comprehended recently. Immunosuppressants represent new treatments in Multiple Sclerosis (MS) but imply a lot of constraints. This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.</brief_summary>
	<brief_title>Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant</brief_title>
	<detailed_description>Multiple Sclerosis is the first cause of neurological handicap in France. The importance of cognitive disabilities, their evaluation and their impact on patients' life have only been comprehended recently. Immunosuppressants represent new treatments in MS but imply a lot of constraints. This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Clinical diagnosis of Relapsing MS since at least 6 months and less than 10 years Neurological state stable since at least 1 month Moderate Handicap (EDSS â‰¤ 5,5) Secondary Progressive MS Patient having an attack Patient having experienced en MS relapse or recovered systemic corticosteroid in the previous 1 month Depressive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Immunosuppressant</keyword>
	<keyword>Quality of life</keyword>
	<keyword>Cognitive function</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
</DOC>